Citation: Jp. Gold et al., Exclusion of mitral valvuloplasty from predictors of mortality for patients undergoing cardiac valve replacements in New York State - Reply, ANN THORAC, 72(2), 2001, pp. 663-663
Authors:
Wencker, D
Borer, JS
Hochreiter, C
Devereux, RB
Roman, MJ
Kligfield, P
Supino, P
Krieger, K
Isom, OW
Citation: D. Wencker et al., Preoperative predictors of late postoperative outcome among patients with nonischemic mitral regurgitation with 'high risk' descriptors and comparison with unoperated patients, CARDIOLOGY, 93(1-2), 2000, pp. 37-42
Citation: El. Hannan et al., Predictors of mortality for patients undergoing cardiac valve replacementsin New York State, ANN THORAC, 70(4), 2000, pp. 1212-1218
Citation: L. Girardi et Ow. Isom, Repair of traumatic aortic valve disruption and descending aortic transection, ANN THORAC, 69(4), 2000, pp. 1251-1253
Authors:
Lee, LY
Patel, SR
Hackett, NR
Mack, CA
Polce, DR
El-Sawy, T
Hachamovitch, R
Zanzonico, P
Sanborn, TA
Parikh, M
Isom, OW
Crystal, RG
Rosengart, TK
Citation: Ly. Lee et al., Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121, ANN THORAC, 69(1), 2000, pp. 14-23
Authors:
Singh, RG
Cappucci, R
Kramer-Fox, R
Roman, MJ
Kligfield, P
Borer, JS
Hochreiter, G
Isom, OW
Devereux, RB
Citation: Rg. Singh et al., Severe mitral regurgitation due to mitral valve prolapse: Risk factors fordevelopment, progression, and need for mitral valve surgery, AM J CARD, 85(2), 2000, pp. 193-198
Citation: M. Charlson et al., Predictors and outcomes of cardiac complications following elective coronary bypass grafting, P ASS AM PH, 111(6), 1999, pp. 622-632
Authors:
Patel, SR
Lee, LY
Mack, CA
Polce, DR
El-Sawy, T
Hackett, NR
Ilercil, A
Jones, EC
Hahn, RT
Isom, OW
Rosengart, TK
Crystal, RG
Citation: Sr. Patel et al., Safety of direct myocardial administration of an adenovirus vector encoding vascular endothelial growth factor 121, HUM GENE TH, 10(8), 1999, pp. 1331-1348
Citation: El. Hannan et al., A comparison of three-year survival after coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty, J AM COL C, 33(1), 1999, pp. 63-72
Authors:
Rosengart, TK
Lee, LY
Patel, SR
Sanborn, TA
Parikh, M
Bergman, GW
Hachamovitch, R
Szulc, M
Kligfield, PD
Okin, PM
Hahn, RT
Devereux, RB
Post, MR
Hackett, NR
Foster, T
Grasso, TM
Lesser, ML
Isom, OW
Crystal, RG
Citation: Tk. Rosengart et al., Angiogenesis gene therapy - Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease, CIRCULATION, 100(5), 1999, pp. 468-474
Authors:
Rosengart, TK
Lee, LY
Patel, SR
Kligfield, PD
Okin, PM
Hackett, NR
Isom, OW
Crystal, RG
Citation: Tk. Rosengart et al., Six-month assessment of a phase I trial of angiogenic gene therapy for thetreatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA, ANN SURG, 230(4), 1999, pp. 466-470
Authors:
Rosengart, TK
O'Hara, M
Lang, SJ
Ko, W
Altorki, N
Krieger, KH
Isom, OW
Citation: Tk. Rosengart et al., Outcome analysis of 245 CarboMedics and St. Jude valves implanted at the same institution, ANN THORAC, 66(5), 1998, pp. 1684-1691